Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii, Naoki Harada, Eric W. Joseph, et al.
Cancer Research (2013) Vol. 73, Iss. 13, pp. 4050-4060
Open Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox, Stephen W. Fesik, Alec C. Kimmelman, et al.
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 11, pp. 828-851
Open Access | Times Cited: 1760
Targeting RAS–ERK signalling in cancer: promises and challenges
Ahmed A. Samatar, Poulikos I. Poulikakos
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 12, pp. 928-942
Closed Access | Times Cited: 1006
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt, Matthew J. Sale, Paul D. Smith, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 10, pp. 577-592
Closed Access | Times Cited: 554
The clinical development of MEK inhibitors
Yujie Zhao, Alex A. Adjei
Nature Reviews Clinical Oncology (2014) Vol. 11, Iss. 7, pp. 385-400
Closed Access | Times Cited: 377
Targeting Alterations in the RAF–MEK Pathway
Rona Yaeger, Ryan B. Corcoran
Cancer Discovery (2019) Vol. 9, Iss. 3, pp. 329-341
Open Access | Times Cited: 373
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan, Xiaoduo Dong, Jiajun Yap, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 353
RAF-MEK-ERK pathway in cancer evolution and treatment
Rahim Ullah, Qing Yin, Aidan Snell, et al.
Seminars in Cancer Biology (2021) Vol. 85, pp. 123-154
Closed Access | Times Cited: 287
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito, Anna Saborowski, Jingyin Yue, et al.
Cancer Cell (2014) Vol. 25, Iss. 5, pp. 697-710
Open Access | Times Cited: 283
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Eunyoung Park, Shaun Rawson, Kunhua Li, et al.
Nature (2019) Vol. 575, Iss. 7783, pp. 545-550
Open Access | Times Cited: 267
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini, Wenlin Shao, William R. Sellers
EMBO Reports (2015) Vol. 16, Iss. 3, pp. 280-296
Open Access | Times Cited: 234
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Md Entaz Bahar, Hyun Joon Kim, Deok Ryong Kim
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 224
Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
Jacob R. Haling, Jawahar Sudhamsu, Ivana Yen, et al.
Cancer Cell (2014) Vol. 26, Iss. 3, pp. 402-413
Open Access | Times Cited: 220
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 203
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 196
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia, Paolo Fava, Filippo Casoni, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1483-1483
Open Access | Times Cited: 151
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 39
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Leah Wilson, Adam J. Linley, Dean E. Hammond, et al.
Cancer Research (2017) Vol. 78, Iss. 1, pp. 15-29
Open Access | Times Cited: 145
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger, James Sipthorp, Simon J. Cook
Pharmacology & Therapeutics (2018) Vol. 187, pp. 45-60
Open Access | Times Cited: 145
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Pui–Kei Wu, Jong–In Park
Seminars in Oncology (2015) Vol. 42, Iss. 6, pp. 849-862
Open Access | Times Cited: 123
Structural basis for the action of the drug trametinib at KSR-bound MEK
Z.M. Khan, Alexander M. Real, William M. Marsiglia, et al.
Nature (2020) Vol. 588, Iss. 7838, pp. 509-514
Open Access | Times Cited: 122
Targeting RAS -mutant Cancers: Is ERK the Key?
Meagan B. Ryan, Channing J. Der, Andrea Wang‐Gillam, et al.
Trends in cancer (2015) Vol. 1, Iss. 3, pp. 183-198
Open Access | Times Cited: 121
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
James Nagarajah, Mina Le, Jeffrey A. Knauf, et al.
Journal of Clinical Investigation (2016) Vol. 126, Iss. 11, pp. 4119-4124
Open Access | Times Cited: 121
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
Yijun Gao, Matthew T. Chang, Daniel J. McKay, et al.
Cancer Discovery (2018) Vol. 8, Iss. 5, pp. 648-661
Open Access | Times Cited: 120
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, et al.
Molecular Cancer Therapeutics (2014) Vol. 13, Iss. 11, pp. 2547-2558
Open Access | Times Cited: 117
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
Dominika Ewelina Butler, Christopher R. Marlein, Hannah F. Walker, et al.
Oncotarget (2017) Vol. 8, Iss. 34, pp. 56698-56713
Open Access | Times Cited: 113
Page 1 - Next Page

Scroll to top